T-vec was shown to induce antigen-specific local and systemic immunity in phase II studies, with an increase in CD8 T cell density in injected and non-injected lesions, increased checkpoint expression (50), and an increase in melanoma antigen-specific T cells (75). Here, CD8A is linked to melanoma.